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Abstract
The persistence of HIV-1 latent reservoirs represents a major barrier to virus eradication in
infected patients under HAART since interruption of the treatment inevitably leads to a rebound
of plasma viremia. Latency establishes early after infection notably (but not only) in resting memory
CD4+ T cells and involves numerous host and viral trans-acting proteins, as well as processes such
as transcriptional interference, RNA silencing, epigenetic modifications and chromatin organization.
In order to eliminate latent reservoirs, new strategies are envisaged and consist of reactivating HIV-
1 transcription in latently-infected cells, while maintaining HAART in order to prevent de novo
infection. The difficulty lies in the fact that a single residual latently-infected cell can in theory
rekindle the infection. Here, we review our current understanding of the molecular mechanisms
involved in the establishment and maintenance of HIV-1 latency and in the transcriptional
reactivation from latency. We highlight the potential of new therapeutic strategies based on this
understanding of latency. Combinations of various compounds used simultaneously allow for the
targeting of transcriptional repression at multiple levels and can facilitate the escape from latency
and the clearance of viral reservoirs. We describe the current advantages and limitations of
immune T-cell activators, inducers of the NF-κB signaling pathway, and inhibitors of deacetylases
and histone- and DNA- methyltransferases, used alone or in combinations. While a solution will
not be achieved by tomorrow, the battle against HIV-1 latent reservoirs is well- underway.
A quarter of a century after the discovery of HIV-1, we are
still unable to eradicate the virus from infected patients.
Highly active antiretroviral therapy (HAART) consists of
combinations of antiretroviral therapeutics targeting dif-
ferent steps of the virus life cycle (e.g. entry, reverse tran-
scription, integration and maturation) used
simultaneously to reduce the risk of viral replication and
the development of drug resistance conferred by the emer-
gence of mutant strains [1-3]. HAART results in a four-
phase decay of viremia [4-7]: (1) an initial rapid loss of
virus due to the clearance of infected activated CD4+ T
cells, which have a very short half-life and survive for
about one day because of viral cytopathic effects or host
cytolytic effector mechanisms; (2) a slower phase of viral
decay owing to the clearance of several cell populations
with a half-life of one to four weeks, such as infected mac-
rophages, partially activated CD4+ T cells and follicular
dendritic cells (FDCs); (3) a third phase of decay corre-
sponding to cells with a half-life of approximately 39
weeks; and (4) a constant phase with no appreciable
decline, caused (at least partially) by the activation of rest-
ing memory CD4+ T cells. During the fourth phase, HIV-1
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plasma viremia normally ranges from 1 to 5 copies of viral
RNA/mL as detected by extremely sensitive RT-PCR assays
[8-10]. Despite the observation that prolonged HAART
treatment is associated with many metabolic disorders
and toxicities [11,12], the prospect of lifelong treatment is
today a necessary evil because interrupting HAART leads
to a rapid viral rebound, attributable to the persistence of
latently-infected cellular reservoirs notably in resting
memory CD4+ T cells [13-15] and probably in other cell
populations [16-18]. Viral reservoirs include cell types or
anatomical sites where a replication-competent form of
the virus persists with more stable kinetics than the main
pool of actively replicating virus [5,19]. Because they
express no viral protein, latently-infected reservoir cells
are immunologically indistinguishable from uninfected
cells and are insensitive to immune clearance and HAART.
The persistence of transcriptionally silent but replication-
competent HIV-1 reservoirs in HAART-treated infected
individuals represents a major hurdle to virus eradication.
To address this problem, a first approach has consisted of
strengthening HAART. This intensification strategy relied
on the administration of additional viral inhibitors in
association with HAART. Despite their cytotoxicity, candi-
date drugs have included hydroxyurea and cyclophospha-
mide. Hydroxyurea inhibits the cellular enzyme
ribonucleotide reductase, thereby decreasing intracellular
deoxyribonucleotide pools and indirectly impeding viral
reverse transcriptase activity [20,21]. Cyclophosphamide
is an alkylating agent that results in cytoreduction and cell
growth arrest, and is used to treat various types of cancers
and immune diseases. However, these compounds have
not been found to decrease the latently-infected reservoirs
in HIV-infected patients [22,23].
The source of the observed persistent steady-state viremia
in HAART-treated patients has been attributed, on the one
hand, to a non-fully suppressive HAART following poor
drug penetration in anatomical sanctuaries such as the
central nervous system (CNS)[24,25]; and, on the other
hand, to the release of virus due to the reactivation of
latently-infected resting CD4+ T cells (or other cellular res-
ervoirs) despite fully suppressive therapy. Several groups
have proposed the existence of a residual continuous HIV-
1 replication, which could constantly replenish the latent
pool. This proposition was based on the observation of
so-called 2-LTR cirle forms of the provirus, whose half-life
should be less than one day reflecting recent rounds of
infection, in the plasma of HAART-treated patients [26-
29]. However, other groups have found evidence that 2-
LTR circles are actually stable and that their apparent
decline reflects dilution following cell division [30,31]. In
addition, intensified HAART would have prevented this
low-level viral replication, and therefore would have
accelerated the decay of the latent pool; but such results
weren't observed [22,23]. Furthermore, several studies
including mathematical modelings of infected cell turno-
ver [5,6,32] and other experimental data [33] suggested
that persistent viremia is likely due to the intrinsic stabil-
ity and reactivation rate of the latently-infected CD4+ T
cell reservoir. Given that memory T cells provide long-
term immunological memory for decades, their mean
half-life can reach 44.2 months. Based upon previous esti-
mation of 106 cells as the latent reservoir size, Siliciano
and colleagues calculated that an average of 60 years of
uninterrupted HAART would be necessary to eradicate
this latent reservoir [34]. The same group has also recently
shown that a source other than circulating resting CD4+ T
cells contributes to residual viremia and viral persistence,
underscoring the importance of extending HIV-1 reservoir
eradication studies to other cell types [35]. Together, these
results argue that the ultimate theoretical potential of
HAART to control viral replication has already been
reached. If the therapeutic goal is virus eradication, then
novel strategies need to be adopted to target and clear the
latent reservoirs. This clearance could be achieved by
inducing HIV-1 replication in latently-infected cells, while
maintaining or intensifying HAART in order to prevent
new spreading infection. Once reactivated, latently-
infected cells will be eliminated by the host immune sys-
tem and/or virus-mediated cell lyses. It should be kept in
mind that a single residual latently-infected cell can in
theory rapidly rekindle the infection. However, a decline
of the HIV-1 reservoir to a level sufficient to allow an effi-
cient control of the infection by the host immune system
might allow for interruptions in therapy ("treatment-free
windows") and would represent important progress in the
treatment of HIV-1.
This review focuses on our current knowledge and under-
standing of the molecular mechanisms involved in HIV-1
transcriptional latency, whose deeper comprehension
could lead to new therapeutic strategies aimed towards
combining HIV-1 gene expression activators with an effec-
tive HAART for decreasing/eradicating the pool of
latently-infected cells. We will detail the more advanced
treatment strategies based on T-cell activation and HDAC
inhibitors, and also discuss the still-in-progress concepts
such as potential treatments targeting Tat-associated fac-
tors and DNA- and histone- methylation.
Pre- and postintegration latency
Two general forms of viral latency have been observed and
can be segregated based on whether or not the virus has
integrated into the host cell genome: preintegration and
postintegration latency (reviewed in [36,37]). Preintegra-
tion latency results from partial or complete block of the
viral life cycle at steps prior to the integration of the virus
into the host genome [30,38]. This block could result
from incomplete reverse transcription as a result of aRetrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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reduced dNTP pool in metabolically inactive cells [39] or
from restriction by factors such as APOBEC3G, a cellular
deoxycytidine deaminase whose action can be counter-
acted by the viral Vif protein [40-43]. The preintegration
complex (PIC) could also fail to be imported into the
nucleus owing to a lack of ATP [44]. Among cellular
restriction factors of retroviral replication, TRIM5α trim-
ers from Old World Monkeys but not from humans
restrict HIV-1 infection, probably by disrupting the
uncoating of virion cores and interrupting the subsequent
intracellular trafficking needed for proviral DNA to enter
the nucleus [45-47]. While linear unintegrated DNA is
suceptible to integration into the host cell genome follow-
ing activation [44], preintegration latency does not appear
to be of clinical relevance because of its labile nature in T
cells (unintegrated forms persist in the cytoplasm of these
cells for only one day and cannot account for the forma-
tion of long-term latently-infected CD4+ T-cell reservoirs)
[48-50]. Of note, unintegrated DNA remains stable for at
least one month in non-dividing but metabolically active
macrophages [51,52], and seems to maintain biological
activity [53]. Most studies on preintegrated (and postinte-
grated) forms of HIV-1 have been conducted in proliferat-
ing T cells. In order to be clinically relevant, these studies
should be extended to other natural host cells of the virus
(such as macrophages and microglial cells).
Postintegration latency occurs when a provirus fails to
effectively express its genome and is reversibly silenced
after integration into the host cell genome. This latent
state is exceptionally stable and is limited only by the
lifespan of the infected cell and its progeny. Several
aspects contribute to the transcriptional silencing of inte-
grated HIV-1 proviruses:
(1) The site of integration. HIV-1 integrates into the host
chromosomal DNA in a non-random manner. Fol-
lowing nuclear import, LEDGF/p75, a transcriptional
coactivator which interacts directly with the viral inte-
grase [54], targets the PIC predominantly to intronic
regions of actively transcribed genes [55-57]. An anal-
ysis of integration sites in purified resting CD4+ T cells
from infected patients on HAART found that the
majority (93%) of silent proviruses is located within
the coding region of host genes [58], although it is
unclear whether these integration events are represent-
ative of defective proviruses or reflect true latency [13].
The finding that latent HIV-1 proviruses integrate in
actively transcribed regions may seem paradoxical
considering the establishment of a transcriptionally
latent state. However, several different mechanisms of
transcriptional interference may clarify this point
(reviewed in [36] and [59]) (see Fig 1): (i) Steric hin-
drance: when the provirus integrates in the same tran-
scriptional orientation as the host gene, "read-
through" transcription from an upstream promoter
displaces key transcription factors from the HIV-1 pro-
moter as previously shown for Sp1 [60] and prevents
the assembly of the pre-initiation complex on the viral
promoter, thereby hindering HIV-1 transcription. The
integrated virus is thought to be transcribed along
with the other intronic regions of the cellular gene, but
is then merely spliced out. This mechanism has been
confirmed in J-Lat cells, a CD4+ T-cell line used as a
model for HIV-1 postintegration latency [61]. Lenasi
and colleagues have shown that transcriptional inter-
ference could be reversed by inhibiting the upstream
transcription or by cooperatively activating viral tran-
scription initiation and elongation. Of note, certain
host transcription factors and/or viral activators,
which bind strongly to their cognate sites, could resist
the passage of "read-through" RNA polymerase II
(RNAPII) [61]. As studies in yeast have demonstrated
that the elongating polymerase is followed by a rapid
refolding of histones in a closed configuration to
counteract transcription initiation at cryptic sites in
the transcription unit [62], chromatin structure and
epigenetic events could also be implicated in tran-
scriptional interference. Conversely, Han et al. [63]
have demonstrated that upstream transcription could
enhance HIV-1 gene expression without significant
modification of the chromatin status in the region
when the provirus is integrated in the same orienta-
tion as the host gene. These partially contradictory
studies have been questioned [64] based on earlier
studies that reported transcriptional interference as
important in repressing viral promoters integrated in
the same orientation as an upstream host gene pro-
moter [60,65,66]. Interestingly, Marcello and col-
leagues [67] have recently reported that an integrated
provirus suffering from transcriptional interference in
basal conditions becomes transcriptionally active fol-
lowing Tat expression; and that this provirus can
switch off the transcription of the host gene within
which it has integrated or can allow the coexistence of
expression of both host and viral genes. Further analy-
sis of the mechanisms exploited by host genes to regu-
late a viral promoter inserted in their transcriptional
unit or by the virus to counterbalance the host gene
control will be needed to completely elucidate these
transcriptional interference events. (ii) Promoter
occlusion: provirus integration in the opposite orien-
tation to the host gene may lead to the collision of
elongating polymerases from each promoter, resulting
in a premature termination of transcription from
either the weaker or both promoters [66,68]. Conver-
gent transcription may also allow for the elongation of
both viral DNA strands. The subsequent formation of
double-stranded RNAs might lead to RNA interfer-
ence, RNA-directed DNA methylation or generation ofRetrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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A simplified view of the multiple mechanisms of transcriptional interference implicated in HIV-1 postintegration latency Figure 1
A simplified view of the multiple mechanisms of transcriptional interference implicated in HIV-1 postintegra-
tion latency. (a) HIV-1 integrates into the host cell genome predominantly in intronic regions of actively transcribed genes 
[55-57]. Transcriptional interference may lead to the establishment of latency by different mechanisms depending at least on 
the orientation of viral integration compared to the host gene. (b) steric hindrance: when proviral integration occurs in the same 
transcriptional orientation as the cellular host gene, "read-through" RNA polymerase II (RNAPII) transcription from the 
upstream promoter displaces key transcription factors (TFs) from the HIV-1 promoter [60] and prevents assembly of the pre-
initiation complex on the viral promoter. The integrated virus is thought to be transcribed along with the other intronic 
regions of the cellular gene, but is then merely spliced out. HIV-1 transcription inhibition could be reversed by hindering the 
upstream transcription or by cooperatively activating viral transcription initiation and elongation; certain host transcription fac-
tors and/or viral activators, which bind strongly to their cognate site, could resist the "read-through" RNAPII passage [61]. This 
phenomenon was also observed following Tat-mediated transactivation of HIV-1 transcription [67]. (c) promoter occlusion: pro-
virus integration in the opposite orientation compared to the host gene may lead to collisions of the elongating RNA polymer-
ases from each promoter, resulting in a premature termination of transcription from the weaker or from both promoters. (d) 
enhancer trapping: an enhancer of one gene (the 5'LTR enhancer of HIV-1 in this case) is placed out of context near the pro-
moter of a second gene (a cellular gene in this case) and acts on the transcriptional activity of this cellular promoter, thereby 
preventing the enhancer action on the 5'LTR.Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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antisense RNAs [69]. (iii) Enhancer trapping: this phe-
nomenon can occur when an enhancer of one gene is
placed out of context near the promoter of a second
gene.
The spatial distribution of genes within the nucleus
contributes to transcriptional control, allowing for
constitutive or regulated gene expression. In this
regard, a recent study has demonstrated a correlation
between HIV-1 provirus transcriptional repression
and its interaction with a pericentromeric region of
chromosome 12 in several clones of J-Lat cells [70]. In
general, heterochromatin lines the inner surface of the
nuclear envelope, whereas transcriptionally active
euchromatin is dispersed in the nuclear core. Here,
however, the peripheral localization of the provirus
was observed even after induction, suggesting that cer-
tain portions of the nuclear periphery could provide
an environment allowing reversible silencing [70].
(2) The pool of available cellular transcription factors. The
5'LTR functions as the HIV-1 promoter and contains
binding sites for several ubiquitously expressed tran-
scription factors, such as Sp1 and TFIID, and inducible
transcription factors, including NF-κB, NFAT and AP-
1. HIV-1 transcription is tightly coupled to the cellular
activation status because both NF-κB and NFAT are
sequestered in the cytoplasm of quiescent T cells and
recruited to the nucleus following T-cell activation.
The relevance of these (and other) transcription fac-
tors in a potential therapeutic strategy based on reacti-
vation of HIV-1 latently-infected cells is discussed
below.
(3) The chromatin organization of the HIV-1 promoter.
Two nucleosomes, namely nuc-0 and nuc-1, are pre-
cisely positioned in the promoter region of HIV-1 in
latently-infected cell lines [71,72] and impose a block
to transcriptional elongation. Following transcrip-
tional activation, nuc-1 (located immediately down-
stream of the transcription start site) is specifically
remodeled [73]. The mechanisms underlying mainte-
nance of a repressive chromatin state of the HIV-1 pro-
virus in latently-infected cells and the factors
implicated in the remodeling of nuc-1 will be further
discussed in association with epigenetic modifications
of the HIV-1 5'LTR region (posttranslational modifica-
tions of the histone N-terminal tails in the promoter
region and DNA methylation status).
(4) The viral protein Tat and Tat-associated factors. In
addition to the need for host transcription factors
binding to their cognate sites in the 5'LTR, HIV-1 tran-
scription is boosted by the viral trans-activating pro-
tein Tat, which interacts with the cis-acting RNA
element TAR (Transactivation response element)
present at the 5'end of all nascent viral transcripts. Sev-
eral host factors, including Cdk9, Cyclin T1 and his-
tone acetyltransferases, are then recruited by Tat to
unravel the transcriptional block at the early elonga-
tion stage. Tat itself or Tat-associated proteins could be
limiting factors for processive transcription in resting
T cells, thereby inducing a latent HIV-1 infection.
These limiting factors are further discussed below.
(5) MicroRNAs and RNA interference. MicroRNAs
(miRNAs) are single-stranded noncoding RNAs of 19
to 25 nucleotides in length that function as gene regu-
lators and as a host cell defense against both RNA and
DNA viruses [74]. Primary miRNAs are sequentially
processed via the nuclear RNases III Drosha and Dicer
to generate mature miRNAs which interact with a
complementary sequence in the 3' untranslated region
of target mRNAs by partial sequence matching, result-
ing in degradation of the mRNA and/or translational
inhibition [75]. Recent publications demonstrate that
miRNAs can also regulate gene expression at the epige-
netic level, by specifically inducing methylation along
the promoter region or by directly generating the
remodeling of the surrounding chromatin [76,77].
The RNA interference pathway constitutes an addi-
tional level of complexity to the viral-host interplay.
First, a cluster of cellular miRNAs was found to be
enriched specifically in resting CD4+  T cells using
microarray technology and has been shown to sup-
press translation of most HIV-1-encoded proteins
(including Tat and Rev, but not Nef), thereby sustain-
ing HIV-1 escape from the host immune response
[78]. More recently, the cellular miRNA hsa-miR29a
has been demonstrated to downregulate the expres-
sion of the Nef protein and, in that way, to interfere
with HIV-1 replication [79]. Moreover, several cellular
factors required for miRNA-mediated mRNA transla-
tional inhibition have been characterized as negative
regulators of HIV-1 gene expression [80]. Second,
HIV-1 can suppress the miRNA-mediated silencing
pathway during infection of cells. Thus, by reducing
the expression of some cellular miRNAs (e.g. miR-17-
5p and 20a) the virus can increase the expression of
the Tat cofactor PCAF (which is otherwise normally
silenced by the miR-17-5p miRNA cluster) and pro-
mote viral transcription [81]. Alternatively, HIV-1
transcripts (such as TAR and nef) can be processed
into miRNAs (nef [82,83] and TAR [84,85]), which
have been suggested to contribute in part to establish-
ing a latent state by directly downregulating HIV-1
transcription or by indirectly recruiting HDACs to the
5'LTR promoter. There are also reports that HIV-1
infection can modulate cellular RNA-interference
(RNAi) activity through the viral Tat protein [86,87]Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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and the TAR RNA [88], notably by moderating DICER
activity. The usefulness of RNAi as a potential inter-
vention against HIV-1 replication has been provoca-
tively suggested by Suzuki et al. [89] who have
employed siRNA targeted against NF-κB-sequences in
the HIV-1 LTR to enforce transcriptional gene silenc-
ing (TGS). Indeed, there is a complex interplay
between HIV-1 replication and the cell's RNAi path-
ways. The potential utility of this virus-host interac-
tion relevant to eradicating latent viral reservoirs has
been reviewed elsewhere ([90] and [91]).
In vitro models for HIV-1 postintegration 
latency
Postintegration latency is established within days follow-
ing acute infection when productively-infected CD4+ T
cells revert to the resting state, becoming memory T cells.
As discussed above, the molecular mechanisms involved
in the establishment and maintenance of latency are mul-
tifactorial and involve many elements of HIV-1 transcrip-
tion. Unfortunately, the study of latency in vivo has been
hampered by the scarcity of latently-infected cells (0.1-1
infected cell per million CD4+ lymphocytes [13]), their
difficult enrichment due to the lack of any viral marker
(avoiding antibody-based purification strategies), and the
high background rate of defective integrated proviruses.
Cell culture model systems have been generated (includ-
ing the ACH2 T-cell line [92] and the promonocytic U1
cell line [93,94]) which show minimal constitutive
expression of HIV-1 genes, but a marked activation of viral
gene expression following treatment with cytokines or
mitogens. These models have revealed many early insights
into the mechanisms of HIV-1 latency, despite the fact
that mutations in Tat (U1) [95] or in its RNA target TAR
(ACH2) [96] have been demonstrated to be causative of
the latent phenotype of the proviruses integrated in these
two cell lines. More recently, J-Lat cells were developed
with an HIV-1-based vector containing an intact Tat/TAR
axis [97]. These cells whose unique provirus carries the
coding sequence for green fluorescent protein (GFP)
instead of the nef gene were selected for a lack of GFP
expression under basal conditions [97]; they allow for the
rapid assessment of HIV transcriptional activity by cyto-
metric detection of GFP epifluorescence. As an alternative,
Ben Berkhout's laboratory has developed stable cell lines
containing an HIV-rtTA variant (in which the Tat/TAR axis
transcription motifs have been inactivated and replaced
by the inducible Tet-ON system [98]). The HIV-rtTA pro-
virus is completely doxycycline-dependent for virus pro-
duction; it contains the original transcription factor
binding sites in the HIV 5'LTR, and infected cells have
been obtained without selection steps avoiding any bias
towards activation markers [99]. However, the constantly
activated and proliferating nature of infected cell lines
does not accurately represent the quiescent cellular envi-
ronment of latently-infected cells in vivo and the improve-
ment of new models nearer to the in vivo situation is an
important goal for HIV-1 research [100]. Interestingly,
new  ex vivo experimental systems based on primary
human CD4+ T cells or primary derived macrophages were
recently developed to study HIV-1 latency in a more phys-
iological context [101-104]. Among those, Bosque and
Planelles infected memory CD4+ T cells (obtained from
naïve T cells purified from healthy donors and activated
under conditions that drive them to become memory T
cells) with a virus defective in Env, which was then pro-
vided in trans [103]. Of note, these cells were kept in cul-
ture in the presence of IL-2, what could disturb the
quiescent state of the cells. Separately, Siliciano's group
developed a new in vitro model of HIV-1 latency using
human primary CD4+ T cells [104]. These cells were trans-
duced with the anti-apoptotic protein Bcl-2 to ensure the
survival of memory CD4+ T cells and infected with a mod-
ified HIV-1 vector in order to increase the yield of latently-
infected cells. The modified HIV-1 vector preserves LTR,
tat and rev genes, and the signaling pathways leading to
viral reactivation are intact. Thus, this model can be used
to study the reactivation of HIV-1 from latency. Collec-
tively, these new models may be helpful to address the
mechanisms implicated in the switch from productive to
latent infection and vice versa, even if they remain techni-
cally difficult to establish and maintain.
T-cell activation-mediated transcription factors 
involved in HIV-1 transcription
The 5'LTR of HIV-1 contains several DNA-binding sites for
various cellular transcription factors, including Sp1 and
NF-κB binding sites which are required for HIV-1 replica-
tion [105,106], whereas other sites, such as NFAT, LEF-1,
COUP-TF, Ets1, USF and AP-1 binding sites, enhance tran-
scription without being indispensable (see Fig 2B).
NF-κB, typically a p50/p65 heterodimer, is sequestered in
the cytoplasm of unstimulated cells in an inactive form
through its interaction with an inhibitory protein from
the family of inhibitors of NF-κB (IKB). Following activa-
tion of the protein kinase C (PKC) pathway, phosphoryla-
tion of IKB by IKK (IKB kinase) leads to its dissociation
from NF-κB and its subsequent polyubiquitination and
degradation by the proteasome pathway. This dissocia-
tion allows NF-κB translocation into the nucleus, and the
transcriptional trans-activation of NF-κB-dependent
genes. In resting CD4+ T cells, both IκBα and NF-κB are
continuously shuttling between the cytosol and the
nucleus, as well as continuously associating and dissociat-
ing; these fluctuations can impact HIV-1 transcription in
these cells [107]. In HIV-1 latently-infected cells, NF-κB
p50/p50 homodimers, which lack the trans- activation
domain found in the p50/p65 heterodimer, recruit the
histone deacetylase HDAC-1 to the LTR, leading to localRetrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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histone deacetylation and to a repressive chromatin struc-
ture in the HIV-1 5'LTR [108] (Fig 3A). Following T-cell
activation, p50/p50 homodimers are displaced by liber-
ated cytoplasmic stores of p50/p65 heterodimers, which
in turn recruit histone acetyltransferases (HATs) (such as
CBP and p300), thereby driving local histone acetylation
[109-112] to enhance transcription (Fig 3B). NF-κB activ-
ity itself is modulated by direct posttranslational acetyla-
tion of the p65 and p50 subunits. These modifications
affect several NF-κB functions, including transcriptional
activation, DNA-binding affinity and IKBα assembly
[113,114]. The p65 subunit of NF-κB additionally stimu-
lates transcriptional elongation by interacting with
RNAPII complexes including Cdk7/TFIIH [115] and
pTEFb [116]. TFIIH/Cdk7 and pTEFb direct the phospho-
rylation of serine-5 and serine-2 residues, respectively, in
the carboxy-terminal domain (CTD) of the RNAPII. These
phosphorylation events are necessary to allow promoter
clearance and efficient transcriptional elongation by
RNAPII. Interestingly, a siRNA targeting conserved tan-
dem NF-κB motifs in the HIV-1 5'LTR was associated with
increased CpG methylation in the 5'LTR and was shown
to suppress viral replication in chronically infected
MAGIC-5 cells [89]. The recruitment of transcriptional
silencing machinery via this siRNA targeted to NF-κB
Transcription factor binding sites and chromatin organization in the 5'LTR and leader region of HIV-1 Figure 2
Transcription factor binding sites and chromatin organization in the 5'LTR and leader region of HIV-1. (A) Rep-
resentation of the HIV-1 genome. The intragenic hypersensitive site HS7 located in the pol gene is indicated. (B) Schematic rep-
resentation of the main transcription factor binding sites located in the 5'LTR and in the beginning of the leader region of HIV-
1. The U3, R, U5 and leader regions are indicated. Nucleotide 1 (nt1) is the start of U3 in the 5'LTR. The transcription start 
site corresponds to the junction of U3 and R. (C) Schematic representation of the nucleosomal organization of the HIV-1 
genome 5' region. Hypersensitive sites HS2, HS3 and HS4 are indicated. The assignment of nucleosome position in this region 
is based on DNase I, micrococcal nuclease and restriction enzyme digestion profiles [72,73]. During transcriptional activation, 
a single nucleosome, named nuc-1 and located immediately downstream of the transcription start site, is specifically and rapidly 
remodeled [73].Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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binding site sequences seems to correlate with transcrip-
tional silencing and HIV-1 latency [89].
In response to TCR-triggered Ca2+ release via the PKC
pathway, cytoplasmic NFAT is rapidly dephosphorylated
by calcineurin and translocates into the nucleus [117].
NFAT interacts with the 5'LTR at sites overlapping the U3
NF-κB binding sites, suggesting mutually exclusive bind-
ing and alternate transactivation by these two factors
[118]. A NFAT downstream binding site was also charac-
terized in the U5 region of the viral 5'LTR [119,120] (Fig
2B). Recruitment of the coactivators p300 and CBP by the
transactivation domains of NFAT proteins [121] suggests
that, like NF-κB, members of the NFAT family could pro-
mote chromatin remodeling of the HIV-1 5'LTR. T-cell
receptor pathway also induces AP-1 dimers, composed of
members of the Jun, Fos and ATF families, by activation of
c-Jun N-terminal kinase (JNK) and extracellular signal-
related kinase (ERK) [122,123]. Studies of host NFAT-
responsive promoters indicate that NFAT binding induces
extensive nucleosomal disruption, in a manner depend-
ent on cooperative binding with AP-1 [124]. Moreover,
Tat interacts with NFAT, increasing its cooperation with
AP-1, without altering independent binding of the AP-1
transcription factors to DNA [125]. These results suggest
that AP-1 can cooperate with NFAT to activate HIV-1 tran-
scription through the U3 NF-κB/NFAT binding sites.
Our laboratory has also identified binding sites for NFAT,
AP-1 and other transcription factors downstream of the
HDAC and HAT recruitment to the HIV-1 5'LTR Figure 3
HDAC and HAT recruitment to the HIV-1 5'LTR. (A) During latency, nuc-1 blocks transcriptional initiation and/or 
elongation because it is maintained hypoacetylated by nearby recruited HDACs. The targeting of nuc-1 by these HDACs is 
mediated by their recruitment to the 5'LTR via several transcription factor binding sites. Thin arrows indicate that the impli-
cated transcription factors were demonstrated to recruit HDACs to the 5'LTR (by ChIP experiments or following knock-
down of the corresponding transcription factor). The dotted arrow indicates that the USF transcription factor could poten-
tially recruit HDAC-3 to the nuc-1 region based on its interactome partners in the literature, but this recruitment has not 
been demonstrated so far in the specific context of the HIV-1 promoter. (B) Nuc-1 is a major obstacle to transcription and has 
to be remodeled to activate transcription. This disruption could happen following local recruitment of HATs by DNA-binding 
factors, and/or by the viral protein Tat, which binds to the neo-synthesized TAR element. This would result in nuc-1 hyper-
acetylation and remodeling, thereby eliminating the block to transcription at least for certain forms of viral latency. This 
acetylation-based activation model has been validated notably regarding the involvement of the transcription factors NF-κB 
p65 and Tat.
YY1
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transcription start site (Fig 2B) [120], in a large nucleo-
some-free region where we had previously identified a
DNase-I hypersensitive site named HS4 [71,120] (Fig 2C).
These downstream binding sites include three AP-1 bind-
ing sites, a NFAT motif, an interferon-responsive factor
(IRF) binding site, and two juxtaposed Sp1 sites, which
are important for viral infectivity [120]. The NFAT motif
lies at the 3' boundary of the nucleosome nuc-1 and may
play a role in nuc-1 remodeling observed following T-cell
activation [126]. The HS4 binding sites constitute an
enhancer that could function independently of, or in con-
cert with, other factors binding to the HIV-1 5'LTR in
order to activate HIV-1 transcription [120].
Analysis of the chromatin organization of integrated HIV-
1 proviruses identified a major hypersensitive site in the
region of 8 kb between the two LTRs. This hypersensitive
site, named HS7 and encompassing nt 4481-4982 (where
nt+1 is the transcription start site) (Fig 2A), is located in
the pol gene between two subdomains (termed the 5103
and the 5105 fragments), both exhibiting phorbol ester-
inducible enhancing activity in HeLa cells [71]. The HS7
site is present only in the U1 cell line of monocyte/macro-
phage origin, and not in the ACH2 and 8E5 cell lines of T-
cell origin. A 500 bp fragment including HS7 positively
regulates transcription from the 5'LTR in transient trans-
fection experiments conducted using T- or monocytic- cell
lines [127]. Multiple transcription factor binding sites
have been identified in the HS7 region. These include
ubiquitously expressed transcription factors such as Sp1/
Sp3, Oct1 and AP-1 and cell-specific transcription factors
such as PU.1, which is only expressed in the monocyte/
macrophage and B-cell lineages [128]. Three AP-1 binding
sites have also been characterized in the 5103 fragment
[129], and our laboratory has recently shown that these
sites are important for viral infectivity (unpublished
results). An additional AP-1 binding site and an Ets-1
binding site were identified in the 5105 fragment (unpub-
lished data from our laboratory). Interestingly, Ets-1 was
recently shown to reactivate latent HIV-1 in an NF-κB
independent manner in a strategy based on transcription
factor expression in order to avoid general T-cell activa-
tion [130]. The intragenic regulatory region (whose com-
plete functional unit is composed of the 5103 fragment,
the HS7, and the 5105 fragment) represents an additional
factor in an already complex network of regulation that
affects HIV-1 transcription.
PKC agonists to induce HIV-1 latent reservoirs
Signaling through PKC was considered as an interesting
pathway to induce latent proviral expression because of
the multiplicity of transcription factor binding sites for
NF-κB, NFAT and AP-1 in the HIV-1 5'LTR and the pol
gene intragenic region. New PKC agonists, including syn-
thetic analogs of diacylglycerol [131], ingenols [132],
phorbol-13-monoesters [133], a jatrophane diterpene
(named SJ23B) [134], and the two non tumorigenic phor-
bol esters prostratin [135,136] and DPP (12-deoxyphor-
bol 13-phenylacetate) [137], have proven capable of
inducing HIV-1 transcription in latently-infected CD4+ T
cells or in PBMCs (peripheral blood mononuclear cells)
from HAART-treated patients. PKC agonists down-regu-
late the expression of the HIV-1 receptor CD4 and the
coreceptors CXCR4 and CCR5 on the host cell surface
[132,138,139]. Therefore, these compounds exhibit inter-
esting bipolar properties as potential molecules to purge
resting T-cell latent reservoirs: they upregulate the expres-
sion of latent proviruses and inhibit the spread of newly
synthesized viruses to uninfected cells via down-regula-
tion of critical receptors necessary for viral entry [140].
The phorbol ester prostratin, found to be the active agent
used by Samoan tribesmen to treat jaundice, is extracted
from the plant Homolanthus nutans [141]. It activates HIV-
1 expression in latently-infected lymphoid and myeloid
cell lines and in primary cells [135-137,139-142] with
minimal effects on the immune system [141] and causes
minimal perturbation of cell cycle progression [142]. Like
bryostatin 1 and DPP, prostratin is an interesting com-
pound as a PKC activator without tumor-promoting activ-
ity. The non-mitogenic property of prostratin, its
remarkable dual role in activating HIV-1 latently-infected
reservoirs without spreading infection, its relatively non-
toxic behavior, and its ability to act on different cell types
make this drug a good candidate for viral purging. Despite
these numerous advantages, the use of prostratin (and
DPP) in human clinical trials awaits safety and toxicity
studies in a suitable primate model [143,144]. However,
preliminary pharmacokinetic studies are encouraging
[135]. Furthermore, chemical synthesis of this therapeuti-
cally promising natural compound in gram quantities and
at low cost was recently reported [145]; this efficient
method of synthesis promises to open the access to
numerous new analogs.
In conclusion, strategies to purge viral reservoirs with PKC
agonists are dependent, at least in part, on the induction
of the cellular transcription factors NF-κB and NFAT/AP-1
by the PKC pathway. These transcription factors bind to
their cognate binding sites in the 5'LTR and in the intra-
genic region of HIV-1 to activate transcription of latent
proviruses.
T-cell activation as a strategy against HIV-1 
latency: Immune Activation Therapy
There has been considerable interest in the possibility that
eradication of latent reservoirs might be feasible through
global cellular activation [146-148]. This strategy is
termed immune activation therapy (IAT). The achievabil-
ity of cytokine-based IAT was proven in vitro with a com-Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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bination of the pro-inflammatory cytokines interleukin-6
(IL-6) and TNF-α, along with the immunoregulatory
cytokine interleukin-2 (IL-2), a combination which was a
potent inducer of viral replication in latently-infected
CD4+ resting T cells isolated from therapy-naïve as well as
HAART-treated patients [149]. Several studies with
patients cotreated with HAART and IL-2 administration
have shown a reduction of CD4+ T cells containing repli-
cation-competent HIV-1 proviruses [150-152]. However,
in these studies, the reemergence of plasma viremia and of
the latent pool within the 2-3 weeks following treatment
interruption suggested that only a partial purge of latent
reservoirs had been reached [150-152]. To additionally
affect HIV-1-infected monocyte/macrophage cells,
gamma-interferon (IFN- γ) was added to IL-2, but a simi-
lar rebound of viremia was observed after ceasing treat-
ment [153]. Later studies attempted to improve the results
of therapy using IL-2 and HAART with the OKT3 anti-
body, which binds the T-cell receptor complex, in order to
deplete T cells [154]. Upregulation of HIV-1 expression
occurred but no demonstrable effect toward purging
latent reservoirs could be obtained [155,156]. In these lat-
ter studies, treated patients experienced over the long term
considerable CD4+ T cell depletion, which was not revers-
ible after treatment interruption [157], and might com-
promise immunity. These patients additionally developed
severe side effects linked to the appearance of anti-OKT3
antibodies due to its murine origin. The side effects were
avoided by the administration of lower doses of OKT3,
leading to a clinically more successful study where the
spectrum of viral genotypes among the rebounding
viruses differed significantly from isolates recovered at the
beginning of the study [147]. This modulation of the viral
pool suggested that the activation of latent proviruses had
happened, but a rebound of plasma viremia still occurred
several weeks after therapy [147].
Using latently-infected cells generated in the SCID/hu
mice model, Brooks et al. have reported that IL-7 is able to
reactivate latent HIV-1 viruses [142]. Moreover, IL-7 has
been shown to induce the in vitro expression of latent HIV-
1 proviruses in resting CD4+ T cells from HIV-infected
patients under HAART treatment [158,159]; and its thera-
peutic potential has been attested based on biologic and
cytotoxicity profiles [160,161]. However, IL-7, such as
other cytokines, induces the proliferation and survival of
CD4+ memory T cells [162], and this property enables a
quantitatively stable pool of latently-infected memory
CD4+ T cells to be maintained in HAART-treated individ-
uals [163,164]. Importantly, Chomont et al. [163] have
very recently shown that different mechanisms ensure
viral persistence in the central memory T cells (TCM) com-
pared to transitional memory T cells(TTM). In the first cell
population, the HIV-1 reservoir persists through cell sur-
vival and low-level antigen driven proliferation. This situ-
ation is observed in HAART-treated patients with high
CD4+ levels. In the second cell population, mainly repre-
sentative of the situation in aviremic patients with low
CD4+ levels, homeostatic proliferation and subsequent
persistence of the cells mediated by IL-7 is implicated in
the maintenance of latent reservoirs. These results incrim-
inate IL-7 specifically (and cytokines in general) in the
maintenance of a reservoir of latently-infected CD4+ T
cells [163], thereby questioning the relevance of immune
activation therapy in the context of a purge of latently-
infected reservoirs in HAART-treated patients.
Chromatin structure and epigenetic regulation 
of eucaryotic gene expression
In eukaryotic cells, DNA is packaged within chromatin to
allow the efficient storage of genetic information. The
structural and functional repeating unit of chromatin is
the nucleosome, in which 146 DNA base pairs are tightly
wrapped in 1.65 superhelical turns around an octamer
composed of two molecules of each of the four core his-
tones H2A, H2B, H3 and H4 [165]. Each nucleosome is
linked to the next by small segments of linker DNA, and
the polynucleosome fiber might be stabilized by the bind-
ing of histone H1 to each nucleosome and successive
DNA linker. Chromatin condensation is critical for the
regulation of gene expression since it determines the
accessibility of DNA to regulatory transcription factors.
Euchromatin corresponds to decondensed genome
regions generally associated with actively transcribed
genes. By contrast, heterochromatin refers to highly con-
densed and transcriptionally inactive regions of the
genome [166].
The chromatin condensation status can be modulated
through a variety of mechanisms, including posttransla-
tional covalent modifications of histone tails and ATP-
dependent chromatin remodeling events [167,168]. ATP-
dependent chromatin remodeling complexes couple the
hydrolysis of ATP to structural changes of the nucleosome
and are divided into three main classes based on their
ATPase subunit: the SWI/SNF family, the ISWI family and
the Mi-2 family [169]. Histone modifications are all
reversible and mainly localize to the amino- and carboxy-
terminal histone tails. They include acetylation, methyla-
tion, phosphorylation, sumoylation, ADP-ribosylation
and ubiquitination. These covalent modifications of his-
tone tails influence gene expression patterns by two differ-
ent mechanisms [170]: (1) by directly altering chromatin
packaging, electrostatic charge modifications or internu-
cleosomal contacts might emphasize or reduce the access
of DNA to transcription factors; (2) by generating interac-
tions with chromatin-associated proteins. These modifica-
tions function sequentially or act in combination to form
the "histone code" and serve as extremely selective recruit-
ment platforms for specific regulatory proteins that drive
different biological processes [171].Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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Histone acetyltransferases (HATs) and histone deacety-
lases (HDACs) influence transcription by selectively
acetylating or deacetylating the ε-amino groups of lysine
residues in histone tails. Generally, chromatin acetylation
by HATs promotes chromatin opening and is associated
with active euchromatin, whereas deacetylation by
HDACs diminishes the accessibility of the nucleosomal
DNA to transcription factors, thereby generating repres-
sive heterochromatin [172]. Moreover, histone acetyla-
tion marks enable the recruitment of bromodomain-
containing proteins, such as chromatin remodeling com-
plexes and transcriptions factors, which in turn regulate
gene expression. HATs and HDACs are usually embedded
in large multimolecular complexes, in which the other
subunits function as cofactors for the enzyme [173]. They
are also involved in the reversible acetylation of non-his-
tone proteins [174]. Humans HDACs have first been clas-
sified into three classes, based on their homolog in yeast
(see table 1, panel a): class I (HDACs 1, 2, 3 and 8), class
II (subdivided into class IIa: HDACs 4, 5, 7, 9 and class
IIb: HDAC 6, 10), and class III (Sirt1 - Sirt7) are homologs
of yeast RPD3, Hda1 and Sir2, respectively [175]. HDAC-
11 is most closely related to class I, but was classified
alone into class IV because of its low sequence similarity
with the other members of class I HDACs. HATs have also
been grouped into different classes based on sequence
homologies and biological functions (see table 1, panel
b): the Gcn5-related N-acetyltransferases (GNATs), the
p300/CBP and the MYST protein families, while several
other not yet classified proteins (such as transcription fac-
tors and nuclear receptor coactivators) have been reported
to possess HAT activity [176].
Histone lysine methyltransferases (HKMTs) and protein
arginine methyltransferases (PRMTs) catalyze the transfer
of one to three methyl groups from the cofactor S-adeno-
sylmethionine (SAM) to lysine and arginine residues of
histone tails, respectively (see table 1, panel c). Histone
methylation has no effect on DNA/histone interactions,
but serves as a recognition template for effector proteins
modifying the chromatin environment. Lysine methyla-
tion has been linked to both transcriptional activation
and repression, as well as to DNA damage responses. In
general, methylation at histone residues H3K4 and
H3K36, including di-and trimethylation at these sites, is
linked to actively transcribed genes, whereas H3K9 and
H3K27 promoter methylation is considered as a repres-
sive mark associated with heterochromatin [177]. How-
ever, methylation at different lysine residues, different
degrees of methylation at the same lysine residue, as well
as the locations of the methylated histones within a spe-
cific gene locus, may affect the functional consequences of
these modifications. Histone methyltransferases (HMTs)
have been classified according to their target (lysine or
arginine) (table 1, panel c). Among the lysine methyl-
transferase's group (HKMTs), a further classification has
been operated based on the presence or absence, and the
nature of the sequences surrounding the catalytic SET
domain [178]. Currently, at least seven SET domain fam-
ilies have been characterized: Suv39, SET1, SET2, EZ, RIZ,
SMYD and Suv4-20 [178]. Until recently, histone methyl-
ation was regarded as irreversible. However, two kinds of
histone demethylases (HDMTs) have been identified: the
LSD1 (lysine specific demethylase 1) family and the
Jumonji C (JmjC) domain family [179], which reverse his-
tone methylation with both lysine-site and methyl-state
specificity (see table 1, panel d).
Studying the implication of these epigenetic marks in the
establishment and maintenance of HIV-1 latency has
opened new therapeutic perspectives for manipulating
epigenetic control mechanisms in order to activate viral
transcription in latently-infected cells. In the next parts of
this review, we draw the current portrait of the epigenetic
control of HIV-1 transcription and we underline the
potential of some new pharmacological agents to address
the purge of the latent reservoirs.
Nucleosomal organization of the 5'LTR of HIV-1
Our laboratory has previously studied the chromatin
structure of integrated HIV-1 proviruses in several
latently-infected cell lines by nuclease digestion methods
[72]. Independently of the site of integration, two nucleo-
somes, named nuc-0 and nuc-1, are precisely positioned
in the 5'LTR in basal conditions, and delineate two large
nucleosome-free regions of chromatin corresponding to
the enhancer/promoter region (nt 200 to 465; HS2+3)
and to a regulatory region located downstream of the tran-
scription start site (called HS4 and encompassing nt 610
to 720) (Fig 2C)[120].
The silent proviral 5'LTR can be switched on from postin-
tegration latency by cell treatment with a variety of stim-
uli, including cytokines (i.e. IL-6 and TNF-α), antibodies
(anti-CD3) or phorbol esters (PMA, prostratin), and by
the viral protein Tat. In order for the transcriptional
machinery to gain access to DNA, the chromatin structure
needs to be altered. The nucleosome nuc-1, located imme-
diately downstream of the transcription start site, is specif-
ically remodeled following PMA or TNF-α treatment of
the cells, coinciding with activation of HIV-1 gene expres-
sion [72,73]. This remodeling includes posttranslational
modifications of histone tails and alterations of the chro-
matin structure by ATP-dependent remodeling com-
plexes, whose importance is described hereafter.
HDACs and HATs recruitment: a switch from 
latent to active transcription
HIV-1 transcriptional activation was shown to occur fol-
lowing treatment with several HDAC inhibitors (HDA-Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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Table 1: Chromatin-modifying enzymes. 
a. HDACs (Histone deacetylases)
Family Members
Class I HDAC-1; HDAC-2; HDAC-3; HDAC-8
Class Iia HDAC-4; HDAC-5; HDAC-7; HDAC-9
Class IIb HDAC-6; HDAC-10
Class III SIRT1; SIRT2; SIRT3; SIRT4; SIRT5; SIRT6; SIRT7
Class IV HDAC-11
b. HATs (Histone acetyltransferases)
Family Members
GNAT Gcn5; ELP3; HAT1; PCAF
p300/CBP p300; CBP
MYST ESA1; CLOCK; MOF/MYST1; HBO1/MYST2; MOZ/MYST3/HAT3; MORF/MYST4; SAS2; TIP60; YBF2/SAS3
Others ACTR; ATF-2; GRIP; p/CIP; SRC1; TAF1; TFIIB
c. HMTs (Histone methyltransferases)
Family Members
HKMTs ALL-1; ALR; AsH1; DOT1L; ESET/SETDB1; EuHMTase/GLP; EZH2; G9a; MLL1; MLL2; MLL3; MLL4; MLL5; NSD1; RIZ1; 
SET1; SET2; SET 7/8; SET7/9; SMYD2; SMYD3; Suv39 h1; Suv39H2; Suv4-20H1; Suv4-20H2
PRMTs PRMT1; PRMT2; PRMT3; PRMT4/CARM1; PRMT5/JBP1; PRMT6
d. HDMTs (Histone demethylases)
Family Members
LSD1 LSD1
JHDM/Jumonji JARID1A/RBP-2; JARID1B/PLU-1; JARID1C/SMCX; JARID1D/SMCY; JHDM1a; JHDM1b; JHDM2a; JHDM2b; JMJD2A; JMJD2B; 
JMJD2C; JMJD2D; JMJD3
e. DNMTs (DNA methyltransferases)
Family Members
Maintenance DNMT1Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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CIs) such as Trichostatin A (TSA), Trapoxin (TPX),
Valproic Acid (VPA) and sodium butyrate (NaBut) either
in cells transiently or stably transfected with HIV-1 LTR
promoter reporter constructs [97,180,181], or using in
vitro chromatin reconstituted HIV-1 templates [182,183],
or in latently-infected cell lines [73], or in de novo infec-
tions [184]. These results indicate that nuc-1 is constitu-
tively deacetylated by HDACs in latent conditions. The
HDACI-mediated transcriptional activation is accompa-
nied by the specific remodeling of nuc-1 and by an
increased acetylation of H3K4 and H4K4 (activating epi-
genetic marks) in the promoter region [111,185].
Several transcription factors binding to the 5'LTR were
demonstrated to recruit HDAC-1 (Fig 3A), whose inhibi-
tion promotes effective RNAPII binding to the HIV-1 pro-
moter region, thereby allowing transcriptional initiation.
A non exhaustive description of transcription factors
which could be implicated in HDACs recruitment is
described below with possible approaches to hinder
recruitment (Figure 3A):
- LSF (Late SV40 Factor) binds to the 5'LTR down-
stream of the transcription start site and recruits YY1
(Ying Yang 1) via a specific interaction with its zinc-
finger domain; YY1 subsequently recruits HDAC-1
[186,187]. Interestingly, pyrole-imidazole polyamides
are small DNA-binding molecules which are specifi-
cally targeted to LSF binding sites and block the
recruitment of HDACs to the HIV-1 5'LTR [185], lead-
ing to a transcriptional activation of HIV-1 in latently-
infected cells [188].
- The unliganded form of thyroid hormone receptor
(TR) decreases local histone acetylation following
HDAC recruitment, while thyroid hormone treatment
reverses this effect by nuc-1 remodeling and transcrip-
tional activation [189,190].
- AP-4 (Activating Protein-4) represses HIV-1 gene
expression by recruiting HDAC-1 as well as by mask-
ing TBP (TATA-binding protein) to the TATA box. This
transcription factor is present concomitantly with
HDAC-1 at the 5'LTR in latently-infected cells and dis-
sociates following TNF-α activation as shown by chro-
matin immunoprecipitation (ChIP) assays [191].
- As described above, NF-κB p50/p50 homodimers
recruit HDAC-1 to repress HIV-1 transcription in
latently-infected cells.
- CBF-1 (C-promoter Binding Factor-1) binds to two
sites embedded within the NF-κB/NFAT enhancer ele-
ment. Knock-down of this factor causes an elevated
H3K4 acetylation level and inhibits HDAC-1 recruit-
ment to the 5'LTR [192].
- Stojanova et al. [193] have shown that the ectopic
expression of c-Myc inhibits HIV-1 gene expression
and virus production in CD4+ T lymphocytes. This
repression could involve c-Myc interaction with the
initiator binding proteins YY1 and LBP-1 (Lipopoly-
saccharide-Binding Protein 1) [193] or c-Myc medi-
ated recruitment of DNMT3A (DNA methyltransferase
3A) to the HIV-1 promoter [194]. Moreover, another
group demonstrated that c-Myc is recruited to the HIV-
1 5'LTR by Sp1 and in turn recruits HDAC-1 in order
to blunt HIV-1 promoter expression [195]. Interest-
ingly, small-molecule reagents that inhibit c-Myc have
entered early clinical testing in oncology [196].
- RBF-2 (Ras-responsive Binding Factor 2) is com-
posed of a USF-1/USF-2 (Upstream Stimulatory Fac-
DNMT2
De novo DNMT3a; DNMT3b; DNMT3l
This table summarizes the main family members of HDACs (panel a), HATs (panel b), HMTs (panel c), HDMTs (panel d) and DNMTs (panel e). To 
facilitate comprehension, enzymes that appear in the text of this review are indicated in bold.
Abbreviations used in table 1: ACTR: Activator of thyroid and retinoic acid receptors; ALL-1: acute lymphoblastic leukemia; ALR: ALL-1 related 
gene; AsH1: absent small or homeotic discs1; ATF-2: Activating Transcription Factor; CARM1: coactivator-associated arginine methyltransferase 1; 
CBP: CREB binding protein; DOT1: disrupter of telomeric silencing; ELP3: elongation protein 3 homolog; ESET: SET domain bifurcated 1; Eu-
HMTase: euchromatic histone methyltransferase 1; EZH2: enhancer of zeste homolog 2; Gcn5: General control nuclear factor 5; GNAT: Gcn5-
related N-AcetylTransferase; GRIP: glucocorticoid receptor-interacting protein 1; HBO1: HAT bound to DNA replication origin complex; HKMT: 
Histone methyltransferase; JARID: Jumonji, AT rich interactive domain; JHDM: JmjC domain containing histone demethylases; JMJD: Jumonji-domain 
containing; LSD1: lysine-specific demethylase 1; MLL: Mixed-lineage leukemia; JBP1: Janus kinase binding protein 1; MOF: males absent on the first; 
MORF: MOZ-related factor; MOZ: Monocyte leukemia zinc-finger protein; MYST: named for its founding members MOZ, YBF2/SAS3, SAS2, and 
Tip60; NSD1: nuclear receptor binding SET domain protein 1; p/CAF: p300/CBP associated factor; p/CIP: p300/CBP interacting protein; PRMT: 
Protein arginine methyltransferase; RBP-2: retinol-binding protein 2; RIZ1: retinoblastoma protein-interacting zinc-finger 1; SAS2: serum antigenic 
substance 2; SET1: SET domain containing 1; SETDB1: SET domain bifurcated 1; SIRT: Sirtuin; SMC: Structural Maintenance of Chromosomes-1; 
SMYD: SET- and MYND-domain-containing; SRC: Steroid receptor coactivator; Suv39 h1: suppressor of variegation 3-9 homolog 1; Suv4-20 h1: 
suppressor of variegation 4-20 h1; TAF1: TATA-binding protein (TBP)-associated factor; TFIIB: Transcription factor IIB; TIP60: Tat interacting 
protein (60 kD).
Table 1: Chromatin-modifying enzymes.  (Continued)Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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tor) heterodimer whose cooperative association with
the transcription factor TFII-I allows binding to the
highly conserved upstream element RBEIII in the HIV-
1 5'LTR [197,198]. HDAC-3 was demonstrated to
modulate some of the functions of TFII-I [199] and
RBEIII site mutation to inhibit HDAC-3 association
with the 5'LTR of HIV-1 [200]. Moreover, the presence
of HDAC-3 in vivo in the HIV-1 5'LTR region has been
demonstrated in Jurkat J89 GFP cells [201]. These
results suggest an implication of RBF-2 in the recruit-
ment of HDAC-3 to the HIV-1 5'LTR but need further
investigation.
- Sp1 binds to three sites immediately upstream of the
core promoter and recruits HDAC-1 and HDAC-2 to
promote histone H3 and H4 deacetylation [202,203].
In microglial cells, the CNS-resident macrophages,
this recruitment requires the cofactor CTIP-2 (COUP-
TF interacting protein 2), as described later in this
review.
All these mechanisms are not mutually exclusive, and they
highlight a unique redundant use of cellular transcription
factors by HIV-1 to maintain quiescence in resting T cells.
These mechanisms depict the complexity of this lentivi-
rus' transcriptional regulation. Moreover, recent studies
suggest a cooperative role in HIV-1 silencing of HDAC-1,
HDAC-2 and HDAC-3, which could functionally substi-
tute for each other [201,204]. Therefore, these redun-
dancy properties could represent a way for the virus to
ensure its replication in various cellular environments.
Following activation, cellular HATs, including p300/CBP,
PCAF and Gcn5, are recruited to the promoter region lead-
ing to the acetylation of both H3 and H4 histones
[111,202]. Several transcription factors have been shown
to interact with HATs (Figure 3B), including AP-1, cMyb,
GR, C/EBP, NFAT [121], Ets-1 [205], LEF-1 [206], NF-κB
p50/p65 heterodimer [114], Sp1, IRF [207] and the viral
protein Tat [208]. Furthermore, the ATPase subunit of
SWI/SNF is recruited to the 3' boundary of nuc-1 by ATF-
3, which binds to the second AP-1 site identified in the
HS4 region, following PMA-mediated activation of Jurkat
T cells [209] and/or by the viral protein Tat [209-212] as
described in details here below. The maintenance of a sta-
ble association between the SWI/SNF subunit BRG-1 and
chromatin appears to be dependent upon histone acetyla-
tion [209].
By altering histones, recruiting other chromatin-remode-
ling factors and modifying the activity of certain transcrip-
tion factors, HDACs (and particularly HDAC-1) appear to
be critical for the epigenetic repression of HIV-1 transcrip-
tion and for the maintenance of latency. Following
recruitment of HATs and chromatin remodeling com-
plexes, nuc-1 disruption allows viral transcriptional acti-
vation to occur.
HDAC inhibitors: near the cure?
We have previously reported that treatment of latently
HIV-1-infected cell lines with HDACIs induces viral tran-
scription and the remodeling of the repressive nucleo-
some nuc-1 [73]. HDAC inhibitors can be classified into
five structural families: short-chain fatty acids (VPA,
NaBut, phenylbutyrate), hydroxamates (TSA, suberoy-
lanilide hydroxamic acid or SAHA, Scriptaid), benza-
mides (MS-275, CI-994), electrophilic ketones
(trifluoromethylketone) and cyclic tetrapeptides (TPX,
apicidin, depsipeptide) [213-215]. They act with varying
efficiency and selectivity on the four different classes of
HDACs and even between the different members of a
same HDAC class [216,217]. In the case of HIV-1, potent
inhibitors specific for class I HDACs might be effective
therapeutics to disrupt latent infection and avoid toxici-
ties that could accompany the global inhibition of mem-
bers of the other HDAC families.
HDACIs present several advantages as a potential induc-
tive adjuvant therapy in association with efficient HAART
to purge latent reservoirs [143,218,219]. They activate a
wide range of HIV-1 subtypes [184] without the toxicity
associated with mass T-cell activation, which would gen-
erate new target cells for neo-synthesized viruses. HDACIs
have even been demonstrated to repress the coreceptor
CXCR4 in a dose-dependent manner [220]. They act on a
broad spectrum of cell types; and therefore, in contrast to
agents that specifically induce T cells, they could target the
different latent reservoirs (macrophages, dendritic cells
and other non-T cells). The most important element
regarding the therapeutic goal resides in the fact that
HDACIs have been safely administered to patients for sev-
eral years in other human diseases: phenylbutyrate in β-
chain hemoglobinopathies such as β-thalassemia and
sickle cell anemia [221,222] and VPA in epilepsy and
bipolar disorders [223,224]. More recently, SAHA (mar-
keted as Vorinostat) was approved by the Food and Drug
Administration (FDA) for treatment of cutaneous T-cell
lymphoma [225]. In the context of many tumor cells,
inhibitors of HDACs have been found to cause growth
arrest, differentiation and/or apoptosis, but to display
limited toxicity in normal cells [226]. Several HDACIs are
engaged in various stages of drug development, including
clinical trials for evaluation of their anti-cancer efficacy
[215].
HDACIs also present certain limitations. General effects of
HDAC inhibition on gene transcription should be a bar-
rier to their wide clinical use. Various studies using cDNA
arrays have shown that between 2% and 20% of cellular
expressed genes are altered in cells exposed to HDACIsRetrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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[215,217,227]. These genes are either activated or
repressed. In addition, numerous non-histone proteins
can be modified by acetylation and, depending on the
functional domain involved, acetylation can alter differ-
ent properties of these proteins such as DNA recognition,
subcellular localization, protein-protein interactions and
protein stability and/or activity. Therefore, inhibition of
HDAC activity affects various biological processes
[228,229]. Moreover, DNA-hypermethylation and subse-
quent compact heterochromatin formation may block the
access of acetylases to their targets, thereby inducing
resistance to HDACIs. Therapeutics that do not directly
inhibit HDACs but that prevent their occupancy or action
at the HIV-1 5'LTR may be considered as an alternative or
an additional approach.
In 1996, VPA was shown to induce HIV-1 expression in
vitro in latently-infected cells [230]. The Margolis group
reported that VPA, in the presence of IL-2, provokes rescue
of replication-competent HIV-1 from purified resting
CD4+ T cells obtained from HAART-treated patients with
undetectable viral load [231]. Next, the same group eval-
uated the ability of clinically tolerable doses of VPA to
deplete HIV-1 infection in a small clinical trial including
four patients. To prevent the spread of infection during
VPA treatment, they intensified HAART with enfuvirtide,
a peptidic fusion inhibitor. After three months of treat-
ment, they observed a modest but significant decline of
the latent reservoir size in three of the four patients [232].
Later reports have failed to show a decay of infected rest-
ing CD4+ T-cell latent reservoir following VPA treatment
[233-236]. More specifically, two of these studies casted
doubt on the effect of VPA, attributing the observed
decline to HAART intensification with enfuvirtide because
they failed to demonstrate a decline of the HIV-1 reservoir
following VPA treatment [233,234]. The other two studies
examining HIV-1-infected patients receiving VPA for neu-
rologic purposes showed either a rapid rebound of plasma
viremia even after two years of treatment [235] or could
not observe a decrease in the size of reservoirs [236]. As
VPA is a weak HDACI, other more potent and selective
HDACIs were explored as therapeutic tools. The FDA-
approved SAHA, a HDACI selective for class I HDACs, was
shown to induce HIV-1 transcription in cell line models of
postintegration latency and in CD4+ resting T cells from
aviremic patients under HAART [204,237]. In the Jurkat
J89 GFP cell model, Archin et al. reported a decreased
HDAC-1 occupancy at the 5'LTR and a concomitant nuc-
1 acetylation following SAHA treatment of the cells [204].
Exposures to SAHA did not upregulate surface activation
markers or receptors required for HIV-1 infection in
PBMCs, which constitute good properties to avoid de novo
infection. SAHA is thus a promising candidate for eradica-
tion of HIV-1-latent reservoirs and is under further inves-
tigation.
In conclusion, in strategies aimed at purging HIV-1 cellu-
lar reservoirs, HDACIs represent a potentially promising
group of pharmacological agents. Among their numerous
advantages, they activate HIV-1 transcription in postinte-
gration latency model cell lines and in PBMCs from
HAART-treated patients. However, at the present time,
studies performed with these compounds, when used
alone, have not reached the expected therapeutic goal, i.e.
the eradication of latent reservoirs in HIV-1-infected
patients.
The viral Tat protein and Tat-associated factors
HIV-1 transcription is characterized by an early Tat-inde-
pendent phase, where the promoter is under the control
of the chromatin environment and cellular host transcrip-
tion factors. This phase is followed by a late Tat-depend-
ent phase, where Tat primarily drives high levels of
transcription (reviewed in [238] and [239]).
In the absence of Tat, transcription is initiated but blocked
at the promoter proximal position in an early elongation
stage (see Fig 4). This block is due to the presence of N-TEF
(negative transcription elongation factor), composed of
two subunits NELF (negative elongation factor) and DSIF
(DRB-sensitive inducing factor) [240,241], as well as to a
repressive chromatin environment. Short abortive tran-
scripts of about 60 nt in length accumulate in the cyto-
plasm [242], but occasional full-length viral genomic
transcripts would allow the synthesis of a few molecules
of Tat sufficient to stimulate HIV-1 transcription. Tat
binds to the stem-loop TAR RNA element present at the
5'end of all nascent viral transcripts and recruits to its N-
terminal domain the factor pTEFb (positive transcription
elongation factor b), composed of the Cyclin T1 and of
the kinase Cdk9 (Fig 4B). This recruitment is enhanced
through Tat acetylation by PCAF on K28, located in the
trans-activation domain of the viral protein [180]. Cdk9
phosphorylates the CTD of RNAPII, promoting efficient
elongation [238,243]. In the presence of Tat, the substrate
specificity of Cdk9 is altered, such that the kinase phos-
phorylates both serine 2 and serine 5 of the CTD instead
of serine 2 alone [244]. In addition, N-TEF phosphoryla-
tion mediated by pTEFb relieves the block to transcrip-
tional elongation [245]. Tat itself is also acetylated on K50
by p300 and Gcn5 in order to promote the release of
pTEFb [246], dissociation of Tat from TAR, and its subse-
quent transfer to the elongating RNAPII complex. Tat can
then recruit PCAF [247,248], which could play a role in
chromatin remodeling following transcriptional activa-
tion. Of note, FRAP experiments showed that the Tat/
pTEFb complex dissociates from the RNAPII complex fol-
lowing transcription initiation and undergoes subsequent
cycles of association/dissociation [249]. At the end of the
elongation process, Tat deacetylation by sirtuin 1 (SIRT1),
a class III protein deacetylase, allows its dissociation fromRetrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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the RNAPII and PCAF complex, and its recycling to initi-
ate a new cycle of transcriptional activation [250] (Fig
4C). This function might be important when the amount
of Tat is a limited factor, especially at the early phase of
infection.
The binding of Tat to TAR also promotes the recruitment
of various cellular cofactors to the HIV-1 5'LTR including
histone-modifying enzymes such as the HATs p300 and
CBP [208] and chromatin remodeling complexes [209-
212,251], likely reinforcing an acetylated and open chro-
matin environment [251]. Tat first recruits the ATP-
dependent remodeling complex SWI/SNF via its interac-
tion with BRG-1 and Ini1 subunits, allowing the initiation
of nuc-1 remodeling [212]. Acetylated Tat on K50 inter-
acts with the subunits BRM and Ini1 of another SWI/SNF
complex [211], which is consequently recruited at the 3'
end of nuc-1 in the 5'LTR and completes nuc-1 remode-
ling to facilitate transcriptional elongation [252]. The his-
tone chaperone hNAP1 also interacts with Tat improving
its stability and increasing the level of chromatin folding,
probably in cooperation with p300 [253]. In addition to
acetylation, Tat itself is subject to other posttranslational
modifications. Indeed, this viral protein can be methyl-
ated by the protein arginine methyltransferases PRMT6 on
its R52 and R53 residues, resulting in a decreased interac-
tion with TAR and counteracting pTEFb complex forma-
tion [254,255]. One or several protein lysine
methyltransferases, at least SETDB1, were demonstrated
to methylate Tat on K50 and K51 residues [256], thereby
competing with acetylation of the same residues. SETDB1
was shown to recruit DNMT3a and HDACs in order to
promote gene silencing and heterochromatin formation
[257,258]. Together, these results suggest that Tat acetyla-
tion is associated with active transcription, whereas Tat
methylation mainly interferes with transcription and pro-
motes HIV-1 latency.
Beside its classically recognized role in induction of tran-
scriptional elongation and chromatin remodeling, Tat
may also influence transcriptional initiation by facilitat-
ing assembly of the pre-initiation complex [239] requiring
Mechanisms of transcriptional activation by the viral protein Tat Figure 4
Mechanisms of transcriptional activation by the viral protein Tat. (A) In the absence of Tat, transcription from the 
HIV-1 5'LTR produces predominantly short mRNAs as a result of the activity of the negative elongation factor N-TEF, com-
posed of NELF and DSIF, which binds to the hypophosphorylated RNA polymerase II and impedes transcriptional elongation. 
(B) Following the synthesis of the first molecules of Tat, this viral protein migrates to the nucleus. Tat then binds to the RNA 
hairpin TAR, located in the 5' region of all nascent HIV-1 transcripts and activates viral transcription by recruiting the positive 
elongation factor pTEFb, composed of Cdk9 and CyclT1. This recruitment is enhanced through Tat acetylation by PCAF on 
K28, located in the transactivation domain of the viral Tat protein. Cdk9 phosphorylates the CTD domain of RNAPII, leading 
to processive transcriptional elongation and to the dissociation of N-TEF. Acetylation of Tat on K50 by p300 and Gcn5 pro-
motes the release of pTEFb [246], dissociation of Tat from TAR and its subsequent transfer to the elongating polymerase com-
plex. Tat then recruits PCAF to the elongation complex. Tat also recruits the ATP-dependent remodeling complex SWI/SNF. 
Another model based on FRAP experiments propose that the Tat/pTEFb complex dissociates from the RNAPII complex fol-
lowing transcription initiation and undergoes subsequent cycles of association/dissociation [249]. (C) At the end of the elonga-
tion process, Tat deacetylation by the class III HDAC Sirtuin 1 allows its dissociation from RNAPII and from PCAF, and the 
recycling of Tat initiates a new cycle of transcriptional activation.
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the Sp1 and NF-κB binding sites, but no consensus about
the mechanisms involved has been reached so far [259-
261]. Increasing evidence suggests that Tat also plays a
role in splicing, capping and polyadenylation processes
[262,263].
In conclusion, Tat acts at several levels in HIV-1 transcrip-
tion. Weinberger and colleagues showed that Tat level
fluctuation is a crucial event that may influence the switch
from a lytic productive state of the infection to a latent
non-productive state [264].
Beside low levels of Tat, latency might also result from low
levels of Tat-associated factors, such as CycT1/Cdk9.
Expression of pTEFb is activated by cytokines IL-2 and IL-
6 [265]. The kinase activity of the complex CycT1/Cdk9 is
constitutively restricted by its association with a small cel-
lular RNA named 7SK, which acts as a scaffold for
HEXIM1, a cellular protein containing a C-terminal pTEFb
inhibitory domain [266]. Hexamethylene bisacetamide
(HMBA) is a clinically tolerable agent [267], first devel-
oped as an anticancer drug, which could be of interest in
the reactivation of the latent reservoirs. HMBA causes the
release of pTEFb from HEXIM1 and triggers Cdk9 recruit-
ment to the HIV-1 5'LTR via an unexpected interaction
with the transcription factor Sp1 [268]. HMBA was shown
to induce gene expression in latently-infected T-lymphoid
and monocytic cell lines, and to provoke a downregula-
tion of the receptor CD4 but not of the coreceptors
CXCR4/CCR5 at the PBMC surface [269]. Pilot human
clinical trials suggest that HMBA, or other analog com-
pounds, might be developed as therapeutics to target HIV-
1 latently-infected cells.
Histone methylation status and 
heterochromatin environment of the HIV-1 
integrated promoter
In addition to histone hypoacetylation, H3K9 trimethyla-
tion is associated with a repressive chromatin status [270].
This epigenetic mark is mediated by the human histone
methyltransferase Suv39 h1. The subsequent recruitment
of HP1 initiates heterochromatin formation, whereas
propagation and maintenance of heterochromatin are
guaranteed via a self-perpetuating epigenetic cycle involv-
ing HP1, Suv39 h1 and H3K9 trimethylation [271]. Inter-
estingly, recruitment of these factors at the HIV-1 5'LTR
has been previously described in microglial cells [203].
Indeed, the group of Rohr in collaboration with our labo-
ratory has demonstrated that the transcription factor Sp1,
which binds to its three cognate binding sites in the 5'LTR,
recruits a multienzymatic chromatin-modifying complex
to the HIV-1 promoter via the transcriptional corepressor
CTIP-2 (Fig 5) [202]. This corepressor was initially identi-
fied in association with members of the COUP-TF family
[272]. CTIP-2 is mainly expressed in the brain and the
immune system [273]. Concomitant recruitment of
HDAC-1, HDAC-2 and Suv39 h1 to the viral promoter by
CTIP-2 allows H3K9 deacetylation, which is a prerequisite
for H3K9 trimethylation by Suv39 h1 [203] (Fig 5). This
last histone modification allows HP1 binding and polym-
erization. Moreover, CTIP-2 itself can recruit Suv39 h1
and the three isoforms HP1α, HP1β and HP1γ of HP1
proteins to the viral promoter [274]. Chromatin modifica-
tions (e.g. H3K9 deacetylation and further H3K9 trimeth-
ylation) appear to be propagated in the downstream nuc-
2 region, suggesting that this heterochromatic structure
spreads along the viral genome [202]. Interestingly, the
Rohr group reported displacement of CTIP-2 and subse-
quent recruitment of CBP through Sp1 following HIV-1
activation with phobol esters [202]. Moreover, the Ben-
kirane's group has demonstrated that Suv39 h1, H3K9 tri-
methylation and HP1γ play a major role in chromatin-
mediated repression of HIV-1 gene expression in systems
other than microglial cells, including HIV-1 infected T-cell
lines and PBMCs from infected individuals [275]. Indeed,
these authors demonstrated an increased level of HIV-1
expression in cultures of primary HIV-1-infected CD4+ T
cells following siRNA knockdown of Suv39 h1 and HP1γ
proteins [275].
In addition to repressing the initial phase of HIV-1 tran-
scription through direct binding to the 5'LTR via Sp1,
CTIP-2 also specifically acts as a potent inhibitor of Tat-
mediated transcriptional activation [274]. By direct inter-
action with Tat N-terminal domain and in association
with a third partner HP1α, CTIP-2 leads to the relocaliza-
tion of this tripartite protein complex Tat-CTIP2-HP1α in
distinct nuclear regions associated with heterochromatin
[274]. These observations strengthen the hypothesis that
the formation of nuclear bodies inhibits HIV-1 gene tran-
scription by sequestering a variety of factors required for
transcriptional activation [276]. Of note, PML (promyelo-
cytic leukemia) bodies are sub-nuclear compartments that
have been shown by certain groups to inhibit HIV-1
through different mechanisms: (i) by modulating the
availability of essential transcription cofactors such as
CyclinT1 [277], thereby regulating Tat-mediated tran-
scriptional trans-activation; (ii) by triggering the exportin-
mediated cytoplasmic export of the Ini1 subunit of the
SWI/SNF complex in association with PML proteins
[278].
These epigenetic silencing elements further participate in
the complexity of HIV-1 latency and represent potent tar-
gets for inducing HIV-1 gene expression in latently-
infected cells. Beside HDACIs, histone methyltransferase
inhibitors (HMTIs) represent new candidate drugs for
purging the HIV-1 latent reservoirs. Despite their compel-
ling interest in cancer therapy, the search for HMTIs is still
at its beginning [279]. SAM-analogs such as methylthio-Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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adenosine,  S-adenosylhomocysteine, or the bacterial
metabolite sinefungin have been developed [280], but
their lack of specificity will require further investigations
to address their effect on host cell gene expression.
Indeed, these compounds affect enzymes other than
HMTs which use SAM as a cofactor, such as DNMTs (DNA
methyltransferases). Three specific inhibitors of lysine
methyltransferases have been described so far: chaetocin,
which specifically inhibits Suv39 h1 [281], 3-dea-
zaneplanocin A (DZNep) [282], and BIX-01294 acting on
the G9a HMT (G9a targets H3K9 and H3K27) [283]. As
Suv39 h1-mediated trimethylation requires the previous
demethylation of H3K4 by LSD1 [284], histone demethy-
lase inhibitors (HDMTIs), such as parnate, could also be
of interest to activate HIV-1 latently-infected cells. Further
studies aiming at identifying new HMTIs should provide
additional compounds to be tested for their possible role
in activation of latent HIV-1 reservoirs.
DNA methylation in HIV-1 latency: an area of 
enhanced interest
CpG methylation of the HIV-1 promoter seems to be an
important epigenetic mechanism that maintains latency
as was previously reported for several retroviruses as
HTLV-1 (Human T-cell leukemia virus) [285,286], and
MMLV (Moloney Murine Leukemia Virus) [287]. Cata-
lyzed by DNA methyltransferases (DNMTs) (Table 1,
panel e), DNA methylation occurs predominantly at cyto-
sine residues located within CpG dinucleotides and is
associated with transcriptional silencing. DNA methyla-
tion may impact transcription in two ways [288]: (i) the
methylated DNA may itself physically impede the binding
of transcription factors to their binding site; (ii) methyl-
ated DNA may be bound by methyl-CpG-binding domain
proteins (MBDs), which in turn interact with HMTs (such
as Suv39 h1) and with HDACs, leading to a repressive
chromatin structure. This link between DNA methylation
Model for CTIP-2-mediated establishment of a heterochromatin environment at the HIV-1 promoter region Figure 5
Model for CTIP-2-mediated establishment of a heterochromatin environment at the HIV-1 promoter region. 
(A) CBP recruitment occurs following HIV-1 activation with phobol esters via CTIP-2, which binds to Sp1 binding sites. (B) 
However, in latent conditions, the corepressor CTIP-2 interacts with the Sp1 transcription factor at three sites in the HIV-1 
5'LTR and consequently recruits HDAC-1 and HDAC-2, leading to H3K9 deacetylation in the nuc-1 region. (C) CTIP-2 then 
recruits the HMT Suv39 h1, which trimethylates H3K9 (a repressive chromatin mark). (D) This latter epigenetic modification 
allows HP1 binding and polymerization, heterochromatin formation and propagation at least to the nuc-2 region, and in fine the 
establishment of HIV-1 silencing [202,203]. This mechanism of viral latency can be revoked by different treatment strategies: 
HDACIs hinder the repressive action of HDACs and specific HMTIs directed against Suv39 h1 could avoid the recruitment of 
this silencing machinery.Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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and histone epigenetic marks is important for our under-
standing of the establishment of a latent infection.
CpG methylation of the HIV-1 5'LTR was first reported in
stably-transfected fibroblasts [289]. At the functional
level, CpG methylation of the HIV-1 promoter was shown
to inhibit transcription in a CAT reporter assay with in
vitro methylated vectors [290,291] and was suggested as a
mechanism to maintain HIV-1 latency in U937 mono-
cytic cells [292]. DNA methylation probably acts by
impairing the binding of several important transcription
factors to the 5'LTR, such as NF-κB, USF and Sp1 [290].
Various anticancer agents including 5-aza-2'deoxycytidine
(5-Aza-CdR), an FDA-approved inhibitor of DNA methyl-
ation used in humans to treat myelodysplastic syndrome
(marketed as Decitabine) [293], were shown to induce
HIV-1 transcription in latently-infected cell lines [294]
and in a doxycycline-dependent HIV-rtTA variant [99].
However the role of DNA methylation in HIV-1 latency
was still controversial, and some laboratories even
reported that CpG methylation did not correlate with
transcriptional silencing [295].
Recently, two groups have independently pointed the
importance of DNA methylation in HIV-1 provirus behav-
ior and latency. Two CpG islands overlapping two regions
in the 5'LTR previously shown to be nucleosome-free and
enriched in transcription factor binding sites were demon-
strated to be hypermethylated in J-Lat cells, a model cell
line for postintegration latency. Methyl-binding domain
protein 2 (MBD-2) and HDAC-2 were shown to be
recruited to the latent HIV-1 promoter via the second CpG
island located downstream of the transcription start site.
MBD-2 might silence transcription by the recruitment of
the NuRD complex, a hypothesis supported by the fact
that HDAC-2 is part of the NuRD complex [296]. Further-
more, although 5'LTR cytosine methylation is not
required to establish latency, latency controlled solely by
transcriptional interference and chromatin-dependent
mechanisms in absence of significant 5'LTR promoter
DNA methylation tends to be leaky and easily reactivata-
ble [297]. In contrast, CpG methylation of the 5'LTR,
probably in concert with repressive histone modifications
(such as low levels of H3K4 dimethylation and of H3
acetylation, and high levels of H3K9 trimethylation), con-
tributes to "lock" the silent state of the provirus by pre-
venting its reactivation [297]. Despite previous
discrepancies about the link between DNA methylation in
the 5'LTR and HIV-1 latency, the importance of this epige-
netic modification is today well established and must be
envisaged in strategies to purge latent reservoirs.
In addition to the four well-characterized nucleoside ana-
log methylation inhibitors, 5-azacytidine (5-Aza), 5-aza-
2'-deoxycytidine, 5-fluoro-2'-deoxycytidine, and zebular-
ine, there is a growing list of non-nucleoside DNA meth-
ylation inhibitors such as procaine, procainamide,
hydralazine and RG108 [298]. Only 5-Aza and 5-Aza-CdR
are currently FDA-approved and used in cancer therapies.
The major hindrance of their usage in humans is their
instability in vivo and the toxicity secondary to their exces-
sive incorporation into DNA, which causes cell cycle
arrest. These cytosine analogs were also shown to induce
proteasomal degradation of DNMT1 [299]. Today, no
clinical study including HIV-1 infected patients or ex vivo
reactivation studies on PBMCs isolated from HAART-
treated patients have been performed using DNA methyl-
ation inhibitors to reduce the pool of latent reservoirs, but
it is an interesting field to explore.
Combination therapy approaches to purge HIV-
1 reservoirs
Current HAART decreases HIV-1 RNA plasma levels below
50 copies/ml but still does not eradicate the virus from
infected patients. Interrupting HAART leads to a rapid
viral rebound attributed to the persistence of latently-
infected cellular reservoirs. Latency is a multifactorial phe-
nomenon: different levels of transcriptional and epige-
netic blocks are involved and probably act in concert to
silence HIV-1 transcription. Altogether DNA- and histone-
methylation and histone deacetylation cooperate to estab-
lish and maintain a repressive chromatin structure of the
HIV-1 provirus in latently-infected cells. Moreover, several
studies in cells from aviremic HAART-treated patients
have shown that targeting latent reservoirs with an
HDACI alone or a PKC agonist alone could decrease the
size of the latent pool, but inevitably led to a rapid viremia
rebound in the several weeks following interruption of the
treatment [233-236]. New strategies attacking simultane-
ously different levels of latency maintenance and/or
establishment should be more efficient when viral eradi-
cation is the objective since the combination of different
types of compounds could synergize in the reactivation of
latently-infected cells.
So called "Shock and kill" strategies are based on activa-
tion of HIV-1 expression followed by stimuli leading to
elimination of infected cells, either naturally (via the host
immune system or viral cytopathic effects), or via a "kill"
phase treatment (with drugs or antibodies). Savarino et al.
have recently combined HDACIs as HIV-1 inducers and
BSO (glutathione-synthesis inhibitor buthionine sulfox-
imine), which creates a pro-oxidant environment and in
turn stimulates HIV-1 transcription [300]. BSO increased
HDACIs ability to induce HIV-1 expression by lowering
intracellular levels of glutathion, thereby allowing the
reduction of both drug concentrations to doses that were
not toxic for uninfected cells. Moreover, BSO induced the
recruitment of HDACIs insensitive cells to the population
of responding cells [300]. This combination thus potenti-Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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ates the action of HDACIs, but different activation strate-
gies may be required to reach each type of latent
reservoirs.
Our laboratory has previously demonstrated a strong syn-
ergistic activation of the HIV-1 promoter activity by the
combination of the HDACI TSA and the NF-κB inducer
TNF-α in the postintegration latency promonocytic model
cell line U1 [184,301]. It is interesting to note that an
array of cytokines, including TNF-α and IL-1, is already
copiously expressed in the environment of lymphoid tis-
sues, and that they could amplify the clinical potential of
HDACIs in patients. However, toxicity of these com-
pounds (TNF-α and TSA) undermines their clinical inter-
est for human therapy. Our laboratory has examined the
HIV-1 reactivation potential of a treatment combining the
non tumor-promoting NF-κB inducer prostratin and sev-
eral HDACIs used in human clinical therapies (such as
VPA and SAHA)[302]. This study demonstrated a syner-
gistic activation of HIV-1 gene expression by these combi-
nations of compounds in latently-infected cell lines
(promonocytic U1 cells and J-Lat T cells). In this latter cell
line, FACS experiments showed the recruitment of
latently-infected cells to the population of HIV-1 actively
expressing cells following the treatment HDACI+pros-
tratin [302]. The observed synergistic activation was
accompanied by the remodeling of the nucleosome nuc-1
as shown by indirect end-labeling experiments. As men-
tioned above, whereas two studies have suggested that
VPA could be a good candidate to deplete latent infection
[231,232], more recent studies did not confirm these
results [233-236,302]. However, the inability of VPA to
reactivate latent reservoirs when used alone showed
potentiating results when used in combination with pros-
tratin [302]. Therefore, when combined with other kinds
of HIV-1 inducers, VPA could have an impact on the decay
of latent reservoirs, despite its weak HDAC inhibitor activ-
ity. Finally, ex vivo cultured CD8+-depleted PBMCs iso-
lated from the blood of aviremic HIV-1-infected patients
under HAART and with undetectable viral load were
treated with these combinations (HDACI+prostratin).
HIV-1 expression was synergistically reactivated in 60% of
the patients tested (25 out of 42 patients) [302]. These
results constitute a proof-of-concept for the co-adminis-
tration of (at least) two different categories of therapeuti-
cally promising HIV-1 inducers together with HAART in
order to decrease the pool of latent HIV-1 reservoirs. How-
ever, 40% of the patient samples didn't show any viral
outgrowth following these treatments. This could result
from a stronger epigenetic control (including DNA and
histone methylation) of the integrated provirus in those
resting cells that would hinder viral transcription and
reactivation.
Wu et al. showed that depsipeptide (an HDACI)-mediated
activation of gene transcription was accompanied by a
decrease of CpG methylation and H3K9 methylation in
the promoter region [303]. These results pointed to a
strong interplay between acetylation and methylation
mechanisms. Moreover, as some latently-infected cells
were reactivated by 5-Aza-CdR and not by TSA, demethyl-
ation seems to be a prerequisite to HDACI transcriptional
activation in certain highly latent reservoirs [297]. Such
combinations of a DNA methylation inhibitor and a
HDACI are used in clinical trials as anticancer treatment
[304]. A combination 5-Aza-CdR/VPA has been tested in
latently-infected cell lines but failed to synergistically reac-
tivate HIV-1 transcription [296]. However, in the same
experiment, the authors showed that inhibiting provirus
methylation leads to an almost complete reactivation of
latent HIV-1 in J-Lat T cells when combined with the acti-
vator of NF-κB signaling TNF-α [296]. In another study, 5-
Aza-CdR was also shown to synergize with prostratin,
which triggers reactivation of latent HIV-1 without broad
T-cell activation and inhibits de novo virus infection [141].
The additional use of DNA methylation inhibitors cou-
pled with a PKC agonist or with a HDACI in antiretroviral
therapy could be a further step to clear the virus from
infected patients.
The study of the epigenetic mechanisms implicated in
HIV-1 latency also indicates the involvement of histone
methylation in the heterochromatin formation process in
the 5'LTR region and suggests a probable effect of HMTIs
and HDMTIs in combinatory strategies to eliminate HIV-
1 reservoirs. Because differences in reactivation patterns
were observed in all patient cell cultures tested, it is
important to evaluate a broader panel of clinically availa-
ble agents and to examine several combinations for each
patient in order to reactivate all kinds of latently-infected
cells and target the different mechanisms implicated in
latency. Such combinatorial approaches, even if they
don't achieve total eradication, could provide important
HIV-1 activation leading to a decline of HIV-1 reservoir
levels sufficient to allow for the efficient control of the
infection by the host immune system, and allow individ-
uals to envisage therapeutic interruptions.
Concluding remarks
HIV-1 latent reservoirs are established early during pri-
mary infection and constitute a major obstacle to virus
eradication. Understanding the complexity of the mecha-
nisms involved in HIV-1 latency and the numerous links
between different control levels of latency requires molec-
ular approaches to determine the most potent targets to
counteract repressive chromatin maintenance and gene
silencing. In a therapeutic goal, the ideal compounds
should be orally available, active but not toxic in a wide
variety of cell types in order to reach HIV-1 sanctuaries
such as the central nervous system and compatible with
the different components of HAART. Since the discovery
of latent reservoirs in the late nineties, the study of HIV-1Retrovirology 2009, 6:111 http://www.retrovirology.com/content/6/1/111
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has followed a path strewn with obstacles, and its eradica-
tion is still far away. However, the growing understanding
of the molecular mechanisms involved in this disease,
and of the virus' unusual talent to escape treatments and
its ability to establish and maintain a latent state in a wide
variety of cells, allows us hope for a therapeutic break-
through. Today, the most promising strategy to eradicate
latent reservoirs resides in combinations of several fami-
lies of compounds to force HIV-1 gene expression simul-
taneously at different levels.
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